FIELD: medicine, pharmaceutics.
SUBSTANCE: group of invention refers to medicine, particularly to producing a mutant antigen GAS57 containing an amino acid modification in two or more positions of amino acids specified in a group consisting of consisting of amino acids D151, H279 and S617 wherein said positions of amino acids are numbered according to SEQ ID N0:1 which is not able to split IL-8 and analogous substrates with keeping an ability to provide protection of the infections caused by S. pyogenes. The group of inventions also comprises a nucleic acid molecule coding a purified mutant antigen GAS57, a method for producing a mutant antigen, a composition and a method for producing it, a method for treating or preventing an infectious disease caused by S. pyogenes. Said mutants may be used inter alia in vaccine compositions.
EFFECT: group of inventions provides protection against S pyogenes infection.
21 cl, 7 ex, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MUTANT SHAPES OF O-STREPTOLYSIN | 2008 |
|
RU2498994C2 |
| MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
| COMPOSITION FOR IMMUNIZATION (VARIANTS), METHOD FOR ITS PREPARING AND USING FOR TREATMENT OF ALLERGIC EOSINOPHILIC DISEASES | 2002 |
|
RU2319503C2 |
| STABILISED FMDV CAPSIDS | 2014 |
|
RU2663004C2 |
| MUTANT HEAT-LABILE ENTEROTOXIN E. coli | 2007 |
|
RU2441879C2 |
| CONJUGATES OF GHRELIN CARRIER | 2003 |
|
RU2325202C2 |
| MUTANT VIRUS OF BULL DIARRHEA | 2006 |
|
RU2394594C2 |
| IMMUNOPROPHYLACTIC CANCER VACCINE | 2004 |
|
RU2556128C2 |
| CLOSTRIDIAL TOXIN NetB | 2008 |
|
RU2474587C2 |
| HAPTEN-CARRIER CONJUGATES AND APPLICATION | 2003 |
|
RU2326693C2 |
